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Background: Potential antigens inducing sarcoid inflammation include mycobacterial and auto-
antigens. Paradoxically, peripheral anergy to common recall antigens also occurs, possibly due
to impaired dendritic cell or regulatory T-cell responses, or impaired T-cell co-stimulation. The
purpose of this study was to compare peripheral blood responses of patients with sarcoidosis to
candidate antigens, and examine CD28 T-cell co-stimulation.
Methods: Peripheral blood mononuclear cell (PBMC) responses were examined from
patients with sarcoidosis (nZ 16) and healthy control subjects (nZ 22) following PBMC
stimulation with: anti-CD3/CD28 coated beads; Mycobacterium tuberculosis ESAT-6 and
KatG peptides; vimentin and lysyl tRNA peptides; and common recall antigens, including
cytomegalovirus (CMV) cell lysate as well as CMV, Epstein-Barr virus, influenza virus
(CEF) peptides.
Results: ESAT-6/KatG peptide stimulation induced greater numbers of IFN-g producing
T-cells, and elevated IL-2, IL-6 and TNF-a production in sarcoidosis compared to purified
protein derivative (PPD)-negative healthy control subjects. PBMCs from patients with
sarcoidosis showed reduced IFN-g producing T-cells following stimulation with CMV lysate,
CEF peptides and CD3/CD28 beads; and reduced IL-4 and TNF-a production following CD3/
CD28 activation.t of Respiratory Medicine, Prince of Wales Hospital, Randwick, NSW 2031, Australia. Tel.: þ61
w.edu.au (H. Ahmadzai), B.Cameron@unsw.edu.au (B. Cameron), jeanie.chui@gmail.com (J.J.Y. Chui),
efield@unsw.edu.au (D. Wakefield), paul.thomas@unsw.edu.au (P.S. Thomas).
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702 H. Ahmadzai et al.Conclusions: Patients with sarcoidosis exhibit greater PBMC responses to M. tuberculosis
antigens compared to PPD-negative controls, but reduced T-cell responses to common
recall antigens. One contributing mechanism may be impairment of T-cell CD28 co-stimu-
lation.
Crown Copyright ª 2012 Published by Elsevier Ltd. All rights reserved.Introduction
Sarcoidosis is a multi-system disorder of unknown aetiology,
characterised by formation of non-caseating granulomas.1
It is associated with abnormal responses to antigens pre-
sented by Major Histocompatibility Complex (MHC) Class II
molecules to CD4þ T-Helper type-1 (TH1) lymphocytes. T-
cells from sites of sarcoid inflammation reveal a restricted
variable-a (Va) and Vb region of the T-cell receptor (TCR),
indicating oligoclonal expansion in response to a limited
number of antigens.2 Vb-specific TCR oligoclonality has
been shown in intradermal responses to Kveim reagent (a
sarcoid splenic extract) in individuals with sarcoidosis.2
Optimal T-cell stimulation also depends on co-
stimulatory molecule binding to appropriate ligands on
antigen presenting cells (APCs).3 TCR-antigen presentation
in the absence of secondary co-stimulatory signals leads to
T-cell anergy or apoptosis.4 CD28 is an important co-
stimulatory molecule, interacting with CD80 and CD86 on
APCs, stimulating IL-2 production and T-cell prolifera-
tion.3,5 Flow cytometric analysis has indicated reduced
CD28 expression on CD4þ cells in peripheral blood and
bronchoalveolar lavage (BAL) of patients with sarcoid-
osis.6,7 Persistence of CD28 cells may have a role in
influencing regulatory T-cell homeostasis in peripheral
tissues.6 This is significant, as sarcoidosis is characterised
by exaggerated inflammation at sites of disease but a sup-
pressed delayed-type hypersensitivity (DTH) skin test and
peripheral blood immune responses.8,9
Antigens associated with sarcoidosis
Bronchoalveolar lavage (BAL) T-cells from HLA-DRB1*0301
patients with sarcoidosis, expressing the Va2.3 (AV2S3) TCR
have been used to identify strong binding peptides to
sarcoid HLA-DRB1)0301 molecules, including those derived
from human vimentin and lysyl tRNA synthetase, which
have been proposed as auto-antigens.10 Subsequent inter-
feron-g (IFN-g) enzyme-linked immunospot (ELISpot) assays
identified T-cell responses to peptides from vimentin in
peripheral blood of DRB1)0301 patients and lysyl tRNA
synthetase in BAL T-cells of both DRB1)0301 positive and
negative patients with sarcoidosis.11
Polymerase-chain reaction techniques have detected
mycobacterial nucleic acids in some sarcoid tissues, although
results were inconsistent.12 Mycobacterial catalase-
peroxidase (KatG) was identified in sarcoid tissue homoge-
nates, andanti-KatG IgG found in thecirculationof sarcoidosis
subjects.13 Investigations indicate greater peripheral blood
mononuclear cell (PBMC) and BALTH1 responses in sarcoidosis
patients compared to healthy controls, but no differences
compared with purified protein derivative-positive (PPDþ)
subjects in response to: Mycobacterium tuberculosis KatG,14heat shock proteins,15,16 Early Secretory-Antigenic Target-6
(ESAT-6),17e19 mycolyl-transferase antigen85A20 and super-
oxide dismutase A.15 Again, these findings have been
inconsistent.21,22
In this current studywe collectively investigate the role of
the major candidate antigens in a cohort of patients with
sarcoidosis. It was hypothesised that PBMC from patients
with sarcoidosis will have greater IFN-g production following
stimulation with M. tuberculosis and also auto-antigenic
peptides derived from vimentin and lysyl tRNA synthetase
than healthy controls. The purpose of this study was thus to
further investigate the immunopathogenesis of sarcoidosis,
by examining T-cell responses and ex vivo cytokine produc-
tion following PBMC stimulation with previously hypoth-
esised candidate antigens and also to investigate the
contribution of CD28 using anti-CD3/CD28 beads.Materials and methods
Study subjects and design
Patients with sarcoidosis attending the Prince of Wales
Hospital Sarcoidosis Clinic and the St. Vincent’s Immu-
nology of the Eye Clinic were invited to participate. This
study was approved by the Human Research Ethics
Committees of the Prince of Wales Hospital and St. Vin-
cent’s Hospital, Sydney, Australia. Informed written
consent was obtained from all participants.
Inclusion required a diagnosis of sarcoidosis prior to
participation, using criteria from the World Association of
Sarcoidosis and Other Granulomatous Diseases.1 All patients
had sarcoidosis, determined by symptoms (acute respiratory
illness, fatigue, sweats, dyspnoea, and dry cough), chest
radiography findings and lung function tests. The diagnosis
was confirmed with either positive biopsies showing non-
caseating granulomas (in the absence of a known cause);
uveitis; a BAL mononuclear cell alveolitis with CD4/CD8 ratio
>3.5; or Lo¨fgren’s syndrome (acute-onset sarcoidosis char-
acterised by erythema nodosum, bilateral hilar adenopathy
and ankle arthritis). Patients with sarcoidosis had PPD
testing and were negative. Healthy controls included those
with documented skin testing to PPD or self-reported history
of vaccination with Bacillus Calmette-Gue´rin (BCG). Healthy
subjects whose PPD skin test and BCG vaccination status
were known were also recorded and classified as either skin
test positive (PPDþ) or negative (PPD).
Peripheral blood mononuclear cell isolation and
storage
Approximately 30 ml of blood was obtained from each
subject in heparinised tubes. PurifiedPBMCwereobtainedby
Peripheral blood responses in sarcoidosis 703Ficoll-Hypaque density gradient centrifugation. Cells were
washed in phosphate-buffered saline (PBS) and cry-
opreserved in 50% autologous serumwith RPMI-1640 medium
(GIBCO Invitrogen, Australia) and 10% dimethyl sulphoxide.
Cells were frozen at 80 C for 24 h before transfer to
vapour-phase nitrogen at 190 C until time of analysis.
Selection and synthesis of T-cell stimuli for ex vivo
analyses
Candidate antigenic peptide sequences fromM. tuberculosis
ESAT-6 and KatG and human vimentin and lysyl tRNA
synthetase, were selected for testing (see Table 1). Addi-
tional peptides selected included Cytomegalovirus, Epstein-
Barr virus and Influenza (CEF) peptides (National Institute of
Health, USA); a panel of 32 pooled HLA-Class I restricted (9-
mer) epitopes, stimulating CD8þ T-cell responses in the
majority of individuals.23 Cytomegalovirus (CMV) cell lysate
was also used,which includes proteins likely to elicit CD4þT-
cell responses.24 These common recall antigens were used to
distinguish sarcoidosis-unrelated responses in patients with
sarcoidosis and healthy control subjects. Pooled M. tuber-
culosis ESAT-6 and KatG peptides, and pooled auto-antigenic
peptides derived from vimentin and lysyl transfer RNA
synthetase were used (Mimotopes, Melbourne, Australia).
These peptides were synthesised using solid-phase 9-
fluorenylmethoxycarbonyl chemistry to an immunograde
purity of>85%. Identity was confirmed bymass spectroscopy
and purity by high-phase liquid chromatography. As a pan T-
cell stimulus, human T-activator CD3/CD28 Dynabeads
(Invitrogen,California,USA)werealsoused.Theseare super-
paramagnetic polystyrene beads conjugated with anti-CD3
and anti-CD28 antibodies, mimicking in vivo TCR T-cell
activation by antigen presenting cells.
IFN-g ELISpot assay
Stimulation of antigen-specific T-cells was assessed using the
human IFN-g ELISpot assay. IFN-g assays were performed as
per the manufacturer’s instructions (R&D Systems, Sydney,
Australia) with thawed PBMCs added at a concentration of
2 105 cells per well of the IFN-g antibody-coated filter
plate. Cells were incubated in duplicate per stimulus. CEF
peptides were added at a concentration of 2 mg/ml, CMV
lysate at a 1:125 dilution in RPMI-1640 medium and myco-
bacterial and auto-antigen peptides at 10 mg/ml as described
previously.11,18 CD3/CD28 beads were also added in separate
wells. Optimisation experiments on healthy subjects
revealed that a ratio of 1 bead:80 cells induced a suitableTable 1 Candidate antigenic peptides in sarcoidosis. Peptides
sarcoidosis. Accession numbers obtained from NCBI BLAST databa
Antigenic peptide Amino acid sequence Amino aci
M. tuberculosis ESAT-6 NNALQNLARTISEAG 66e80
M. tuberculosis KatG WTNTPTKWDNSFLEI 321e335
Homo sapiens vimentin DSLPLVDTHSKRTLL 263e277
Homo sapiens lysyl transfer
RNA synthetase
GPEGQAYDVDFTPPFR 363e378number of spots per well to allow reliable counting and
statistical analysis. Phytohaemagglutinin A (SigmaeAldrich,
Sydney, Australia) was used as a positive assay control at
5 mg/ml, and non-stimulated wells containing media only as
a negative control. As a measure of inter-assay variability,
cells from one subject found to respond strongly to CEF
peptides were tested in each plate (the inter-assay coeffi-
cient of variance was <6%).
Cells were incubated with each stimulus at 37 C in
a humidified atmosphere of 5% CO2 for 24 h, and subse-
quently developed according to manufacturer’s instructions
(R&D Systems, Sydney, Australia). Plate membranes dis-
playing spots were scanned and counted using the AID
ELISpot plate reader system and software version 5.0 (AID
Diagnostika, Germany). Results are presented as the mean
spot-forming cell count (SFC) for duplicate wells after
subtraction of the mean negative control (background)
number of spots. Negative wells had <50 SFC per 2 105
input cells. A positive response was defined as a concen-
tration of at least 50 SFC per 106 PBMCs after subtraction of
background, being at least three times higher than the
background level.
Multiplex cytokine analysis of PBMC culture
supernatants
Following 24 h ELISpot incubation, supernatants were
extracted and stored at 80 C until time of analysis.
Supernatants were collected from cultures stimulated with
CEF peptides, CD3/CD28 beads, ESAT-6/KatG peptides and
non-stimulated wells. A Bio-Plex assay (Bio-Rad Laborato-
ries, Hercules, USA) was used to quantify supernatant levels
of IL-2, IL-4, IL-6, IL-10 and TNF-a according to the manu-
facturer’s instructions. Cytokine measurement was per-
formed using the Luminex 100 xMAP system (Luminex,
Austin, USA) and data analysis with Bio-Plex Manager soft-
ware version 5.0 (Bio-Rad Laboratories).
Statistical analyses
Data was analysed using GraphPad Prism version 5.03
(GraphPad, La Jolla, USA). Non-parametric comparisons of
differences between healthy control subjects and patients
were performed using the ManneWhitney U-test for inde-
pendent data, and the KruskaleWallis test followed by
Dunn’s post-test for comparison between groups. Categor-
ical comparisons were analysed using Fisher’s exact test.
All p-values are two-tailed and p-values <0.05 considered
significant.previously determined to be antigenic in some patients with
se (http://blast.ncbi.nlm.nih.gov/Blast.cgi).
d position (codons) GenBank accession number Gene ID
NP338543 922546
NP216424 885638
AAA61282 7431
EAW95623 3735
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Thirty-eight subjects were recruited, including sixteen with
sarcoidosis (see Table 2). Subjects with sarcoidosis exhibited
relative peripheral blood lymphopenia, a feature of this
disease,5with ameanwhite cell count (standard deviation)
of 5.7 2.1 106/ml compared to 6.4 1.5 106/ml in
healthy subjects (pZ 0.27), of which the lymphocyte
percentage was 24% 0.08% in sarcoidosis patients and
35% 0.05% in healthy subjects (p< 0.0001). Additionally,
patients had elevated median serum ACE of 54.5U/L (normal
range< 42U/L). Patients with sarcoidosis had lower
percentage predicted FEV1 values of 86.1% 17.8%
compared to 98.8% 9.7% in controls (p< 0.05); and lower
percentage predicted FEV1/FVC ratios of 93.3% 15.6%
compared to 102.8% 4.4% in healthy controls (p< 0.05).Table 2 Subject characteristics data are presented as mean
patients with sarcoidosis and healthy control subjects (**p< 0.00
tests, with significance value at 0.05. ACE, Angiotensin convertin
vital capacity; WCC, white cell count; N/A, not assessed.
Sarc
(nZ
Female/male 5/11
Age (years); median (min, max) 49 (3
Disease duration prior to this study (years) 7.5
Serum ACE (U/L) median (min, max)
(Normal< 42U/L)
54.5
Blood WCC (106/ml) 5.7
Lymphocytes (%)** 24%
Monocytes (%) 6.0%
Neutrophils & eosinophils (%)** 70%
Pulmonary function
Mean FEV1 (% predicted)* 86.1
Mean FVC (% predicted) 93.7
FEV1/FVC ratio (% predicted)* 93.3
Chest X-ray stage (0/I/II/III/IV)a 1/6/
Smoking status (current/past/never) 0/9/
Affected organs
Lung 15
Eye (uveitis) 10
Lymph nodes 13
Skin 5
Neurosarcoid 3
Othersb 5
Lo¨fgren’s syndrome 2
Immunosuppressive treatment (yes/no) 4/12
Mantoux skin test & BCG status (PPDþ/PPD )c 0/16
a Pulmonary disease was scored using the 1961 Scadding sarcoidos
involvement), Stage I (bilateral hilar lymphadenopathy), Stage II (
Stage III (parenchymal infiltrates) and Stage IV (pulmonary fibrosis).
b Others is defined as liver, kidney, spleen, lacrimal and salivary gla
c Healthy controls were categorised as those who had a positive PPD
called PPDþ) and those who were PPD skin test negative or whose PPD
BCG, hereafter referred to as PPD).All subjects responded to CD3/CD28 bead stimulation at
varying levels, but not all responded to peptide stimulation
(see Table 1 in Supplementary material). A greater median
IFN-g SFCwas found inhealthy subjects compared topatients
with sarcoidosis following stimulation with CEF peptides
(pZ 0.037, Fig. 1A), with 14/22 (63.6%) healthy subjects
with positive ELISpot responses compared with 6/16 (37.5%)
patients with sarcoidosis. Similar findings were observed
with CMV lysate stimulation (pZ 0.01, Fig. 1B), with 13/22
(59%) positive responses in healthy controls compared with
5/16 (31.3%) responses in patients with sarcoidosis.
PBMCs from patients with sarcoidosis had greater
numbers of IFN-g producing cells reactive to pooled M.
tuberculosis ESAT-6 and KatG peptides compared to PPD
controls (pZ 0.019, Fig. 2A). There was also a significant
difference in the frequencies of positive responders, with one standard deviation. Significant differences between
01, *p< 0.05), p-values based on two-tailed independent t-
g enzyme; FEV1, forced expiratory volume in 1 s; FVC, forced
oidosis
16)
Healthy controls
(nZ 22)
p-Value
9/13 ns
2, 83) 39 (22, 82) ns
6.7
(7.2, 107) N/A
2.1 6.4 1.5 ns
0.08% 35% 0.05% <0.0001
 0.02% 6.0% 0.02% ns
0.09% 59% 0.06% <0.0001
 17.8 98.8 9.7 < 0.05
 15.4 98.4 9.5 ns
 15.6 102.8 4.4 < 0.05
6/1/2
7 1/5/16
None
5/17
is chest X-ray staging system, Stage 0 disease (no intra-thoracic
bilateral hilar lymphadenopathy with parenchymal infiltrates),
nds.
skin test history or prior BCG vaccination (PPDþ/BCGþ, hereafter
status was unknown, or had no history of BCG vaccination (PPD/
Figure 1 ELISPOT PBMC responses to CEF peptides and CMV-infected cell lysate. (A, B) Number of IFN-g spot-forming cells per 106
input PBMC following stimulation with CEF peptides (A) and CMV lysate (B). Bars represent medians and interquartile ranges.
Peripheral blood responses in sarcoidosis 70510/16 patients responding compared to 4/17 PPD controls
(pZ 0.036). However, there was no difference between
patients with sarcoidosis and PPDþ control subjects
(pZ 0.32, Fig. 2A), with 5/5 PPDþ controls responding to
pooled ESAT-6/KatG peptides. As expected there was also
a significant difference in IFN-g SFC to these mycobacterial
peptides, between PPD and PPDþ control subjects
(pZ 0.01, Fig. 2A) and also in the frequency of subjects
responding (p< 0.005, Fisher’s exact test). No difference
was identified between IFN-g production following stimu-
lation by pooled peptides from vimentin and lysyl tRNA
synthetase (pZ 0.91), with 1/16 patients and 4/22 control
subjects responding (Fig. 2B).
There were significantly fewer IFN-g SFC per 106 PBMC
formed by T-cells from patients with sarcoidosis compared
to both PPD and PPDþ healthy control subjects after CD3/
CD28 bead activation (pZ 0.0007, Fig. 3A). Immunosup-
pressant treatment did not appear to significantly alter
CD3/CD28 responses in the patients (pZ 0.43), although
a trend towards lower median SFC was observed in those
taking immunosuppressants.
PBMC culture supernatants were available from 10
healthy control subjects (of whom 5 were PPD), and 11
patients with sarcoidosis. These included all PPDþ
subjects, and based on sample availability, PPD-negative
control subjects and patients with sarcoidosis. Comparative
analyses did not identify any significant differences
between these subject groups for unstimulated PBMCFigure 2 Mycobacterial and auto-antigen responses. (A, B) Mea
stimulation with (A) pooled M. tuberculosis ESAT-6 and KatG peptid
PPD control subjects. (B) Responses following stimulation with po
RNA synthetase in healthy controls and patients.culture supernatants (Table 3A), or following stimulation
with CEF peptides (Table 3B). However, in cell cultures of
sarcoid PBMCs activated with CD3/CD28 beads, there were
lower concentrations of IL-4 and TNF-a (pZ 0.045 and
pZ 0.049 respectively) compared with control subjects,
and a trend for IL-2 and IL-6 (pZ 0.052 and pZ 0.056
respectively) (Table 3C). Following ESAT-6/KatG peptide
stimulation, there were significant differences in produc-
tion of IL-2 (pZ 0.02), IL-6 (pZ 0.04) and TNF-a (pZ 0.02)
between PPD control subjects and patients with sarcoid-
osis (see Table 4), and a trend for IL-10 (pZ 0.07) between
these groups. There were no differences between patients
with sarcoidosis and PPDþ control subjects.Discussion
This study indicates that mycobacterial ESAT-6 and KatG
peptides induced greater numbers of IFN-g producing T-cells
from sarcoidosis subjects compared with PPD-negative, but
not PPDþ controls. Numbers of IFN-g producing T-cells and
ex vivo cytokine production were however, reduced in
patients with sarcoidosis following CD3/CD28 activation and
stimulation with common recall antigens.
Previous findings indicate reduced CD28 signalling
pathway function in T-cells from patients with sarcoid-
osis.6,7 One study identified increased CD4þCD28 T-cells
in BAL and peripheral blood of patients with chronicsurement of IFN-g producing PBMCs with ELISPOT, following
es in PBMCs from patients with sarcoidosis and healthy PPDþ or
oled peptides derived from human vimentin and lysyl transfer
Figure 3 CD28-dependent T-cell activation responses. (A) Number of IFN-g producing T-cells, following CD3/CD28 bead acti-
vation. (B) Number of IFN-g producing T-cells following CD3/CD28 activation, after subdividing the controls into PPD healthy
controls and PPDþ.
706 H. Ahmadzai et al.sarcoidosis, with reduced baseline IFN-g and TNF-
a production when compared with CD28þ T-cells.6 The
authors did not show that these CD4þCD28 T-cells also
had lower capacity for antigenic responses. These findings
were however, in contrast to those of Agostini et al.,25
who identified greater frequencies of BAL T-cells
expressing CD28, but not CD152, in patients with
untreated sarcoid alveolitis, compared to healthy
controls. Agostini et al. demonstrated that enhanced CD28
expression was associated with increased cell surface
expression of activation antigens, including CD69, CD103
and HLA-DR. Other studies7,26 identified reduced CD28
expression by BAL and peripheral blood T-cells from
patients with chronic sarcoidosis, along with elevated cell
surface activation markers CD26, CD69 and HLA-class II inTable 3 Measurement of cytokine concentrations PBMC cultur
culture supernatants: (A) Unstimulated PBMC cultures indicating b
activation by CD3/CD28 beads. Data are all presented as medians
Tested
cytokines
Healthy
controls (nZ 9)
A. Background responses
IL-2 2.4 (0.06e3.57)
IL-4 0.2 (0.03e1.36)
IL-6 8748.1 (7.95e11,123.02)
IL-10 48.9 (0.25e139.33)
TNF-a 4976.2 (5.82e8510.54)
B. CEF peptides
IL-2 4.9 (0.88e137.29)
IL-4 0.2 (0.03e0.74)
IL-6 9083.1 (9.15e18,798.33)
IL-10 67.2 (0.02e139.57)
TNF-a 4898.5 (7.81e20,091.56)
C. CD3/CD28 activation
IL-2 1181.7 (598.37e1852.7)
IL-4 1.4 (0.74e4.54)
IL-6 13,748.6 (13.84e24,789.87)
IL-10 90.2 (9.06e213.25)
TNF-a 8603.3 (491.99e36,964.04)
* refers to p < 0.05.BAL. Although these results appear conflicting, the rela-
tive expression of CD28 may have clinical significance in
sarcoidosis. CD28 elevation in conjunction with reduced
CD152, elevated CD80, CD86 and cell surface activation
markers in BAL T-cells suggest T-cell activation, leading to
compartmentalised lung inflammation. In contrast, CD28
reduction in both peripheral blood and BAL T-cells may
indicate chronic systemic T-cell activation leading to
T-cell senescence and anergy. Hence the relative expres-
sion of CD28 may reflect the activity and chronicity of
disease, and may be useful as a marker of acute or
ongoing antigen-driven inflammation,26 although further
investigations are warranted.
A profile of CD28 down-regulation and anergic T-cells
producing less pro-inflammatory cytokines (IL-6 and TNF-a)e supernatants. Cytokine concentrations (in pg/ml) in PBMC
ackground responses, (B) stimulation by CEF peptides, (C) cell
, ranges in parentheses, p-values from ManneWhitney U-test.
Sarcoidosis patients
(nZ 11)
p-Value
1.1 (0.06e12.67) 0.22
0.2 (0.03e1.21) 0.87
9485.7 (8.6e20,510) 0.36
50.3 (0.04e173.91) 0.94
5934.1 (4.5e25,590.79) 0.19
1.5 (0.52e36.12) 0.15
0.2 (0.03e0.57) 0.42
1406.5 (0.05e22,417.84) 0.23
68.3 (0.02e174.11) 0.68
6972.4 (5.38e28,907.01) 0.34
709.4 (142.44e2099.90) 0.052
0.8 (0.03e1.78) 0.045*
1885.2 (6.13e17,815.97) 0.056
55.1 (0.44e159.54) 0.11
2444.3 (56.3e6709.12) 0.049*
Table 4 PBMC culture supernatants cytokine concentrations following ESAT-6/KatG stimulation. Cytokine concentrations
(pg/ml) in PBMC culture supernatants following ESAT-6/KatG peptide stimulation. p-Values in the left column are from
a ManneWhitney U-test for comparison between sarcoidosis patients and PPD controls. One additional PPDþ subject was
included for testing mycobacterial peptide responses. p-Values in right column compare responses between PPDþ & sarcoid
patients, from ManneWhitney U-test.
Tested
cytokines
Healthy PPD controls
(nZ 5)
p-Value Sarcoidosis
patients (nZ 11)
p-Value Healthy PPDþ controls
(nZ 5)
IL-2 0.08 (0.03e0.61) 0.025* 1.0 (0.06e11.78) 0.92 1.4 (0.03e2.16)
IL-4 0.2 (0.03e0.29) 0.89 0.2 (0.03e0.39) 0.34 0.2 (0.03e0.57)
IL-6 3839.9 (485.5e17,003) 0.039* 15,055.7 (1297.27e21,710.41) 0.99 12,034.3 (10,389.1e19,719.5)
IL-10 0.1 (0.125e261.9) 0.068 117.9 (8.63e258.97) 0.47 202.7 (70.16e212.67)
TNF-a 3180.1 (614.14e6201.6) 0.023* 12,755.0 (1172.6e50,491.1) 0.72 6303.4 (6300.0e8510.7)
* refers to p < 0.05.
Peripheral blood responses in sarcoidosis 707has been shown in other chronic inflammatory disorders.6
It has been hypothesised that chronic T-cell stimulation
with insoluble mycobacterial antigens complexed as
haptens in sarcoid granulomas allowing for slow antigen
removal leads to clonal T-cell exhaustion or anergy.14,27
Similarly, Mycobacterium leprae antigens have been
shown to induce T-cell anergy in vitro by altering TCR/
CD28 signalling pathways.28 Defective TCR/CD28 signalling
pathways and T-cell hyporesponsiveness have been iden-
tified to occur and is the mechanism by which anergy
occurs in patients with leprosy.29 Stimulation with M.
leprae total cell wall antigen has been shown to decrease
PBMC expression of CD28 and CD80 in patients with leprosy
compared with healthy controls.30 In sarcoidosis, evidence
also indicates impairment of signal transduction pathways
via the TCR/CD3 complex. Mechanisms include reduced
expression of nuclear transcription factor NF-kB/p65 and
lymphocyte-specific protein tyrosine kinase (p56LCK) in
sarcoid CD4þ T-lymphocytes, with reduced INF-g and IL-2
production following polyclonal activation.27 Together
with findings from this study and the putative aetiological
role of mycobacterial antigens in sarcoidosis,14,15 this
could indicate that certain mycobacterial antigens alter
TCR/CD28 signalling pathways inducing T-cell anergy in
sarcoidosis.
CD28 T-cells exhibit reduced antigen receptor diver-
sity, defective antigen-induced proliferation and shorter
replicative function.31 This may explain the “all-or-none”
type of response observed in sarcoidosis patients to CEF and
CMV antigens, however, these factors are also influenced by
host immunogenetic factors and presence of specific
memory cells. Although not performed due to a limited
number of cells available for experimentation, it would
have been useful to identify the relative cell surface
expression of CD28 in all subjects and correlate this with
responses to recall antigens. The functional role of CD28
expression in controlling such responses to common recall
antigens in sarcoidosis is hence not well known and requires
further investigation.
CD28 plays a critical role in the maintenance of
peripheral immunological tolerance, by contributing to
development and survival of CD4þCD25bright FOXP3þ
TRegs
32. These cells are peripherally expanded in sarcoidosis
and have anti-proliferative activity but are insufficient tocontrol exaggerated local granulomatous inflammation.8,33
This study also indicates for the first time that PBMC from
patients with sarcoidosis exhibit reduced CD4þ immune
responses after CEF peptide stimulation and reduced CD8þ
responses after CMV lysate stimulation, consistent with
findings in relation to other antigens.8,9 Other mechanisms
of anergy demonstrated in sarcoidosis include diminished
myeloid dendritic cell function, correlating with impaired
DTH skin responses.8 Immunoregulatory invariant natural
killer T-cells are also reduced in BAL and blood of patients
with sarcoidosis and may have a role in peripheral TH1
down-regulation and, exaggerated local sarcoid immune
responses.9,34 The present study could be extended by
examining the relationship between these cell types, along
with CD28 signalling and anergy.
In this study PBMC from sarcoidosis patients had
greater numbers of IFN-g producing PBMC and increased
production of IL-2, IL-6 and TNF-a following stimulation
with M. tuberculosis ESAT-6 and KatG peptides compared
to PPD controls. The observed cytokine production
following ESAT-6/KatG stimulation14e19 displays polarised
TH1 responses and increased IL-6 and TNF-a production;
key factors in granuloma formation.35 Our findings are
consistent with reports of elevated IL-2, IL-6, IFN-g and
TNF-a in sarcoid PBMC culture supernatants following
mycobacterial heat shock protein stimulation.16 The
limitations in this study include possibility of selection
bias in the cytokine production analysis by using super-
natants from a subset of subjects, selected based on
sample availability.
Another limitation in this study was that HLA-typing was
not performed to verify appropriate alleles for recognition
of the candidate antigens studied. It has been found that
HLA-DRB1)0301 BAL T-cells respond to KatG14 and immune
recognition of ESAT-6 and KatG peptides are associated
with HLA-DRB1)1101.17 The lack of differences in IFN-g SFC
between patients and healthy controls in response to auto-
antigenic peptides from vimentin and lysyl tRNA synthetase
may have reflected subject HLA genotypes.
Conclusions
These findings indicate that following CD3/CD28 T-cell
activation in sarcoidosis, there is less production of IFN-g,
708 H. Ahmadzai et al.IL-4 and TNF-a compared to control subjects. Additionally,
there were depressed immune responses to recall antigens,
indicating peripheral anergy. Significantly greater IFN-g and
TNF-a responses to mycobacterial ESAT-6/KatG peptides
were identified in patients with sarcoidosis compared to
PPD controls. The findings also confirmed previous reports
that despite negative mycobacterial culture and histology
findings in sarcoidosis, certain mycobacterial antigens
induce specific immune responses at similar frequencies as
PPDþ subjects.
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